S&P: Abbott remains on watch

Standard & Poor's said its AA/A-1+ long- and short-term ratings on Abbott Laboratories remain on CreditWatch, where they were placed with negative implications in October 2011.

The CreditWatch listing reflects the smaller business risk profile and uncertain financial risk profile of the remaining operations at Abbott, S&P said.

Precisely which pharmaceuticals will remain with Abbott is uncertain, although the emerging-market focus is clear, the agency said.

Abbott's pharmaceutical segment now accounts for the majority of earnings and cash flows with little significant product concentration, S&P said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.